Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 50,357 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Clear all
Completed Phase 2Phase 3 Interventional

Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer

NCT00136487
View directory record Official record
Conditions
Prostate Cancer
Interventions
Celecoxib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
9
States / cities
Hartford, Connecticut • Boston, Massachusetts • Concord, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2009 · Synced Oct 29, 2026, 5:59 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

NCT06110793
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Lenvatinib, Pembrolizuma, Fulvestrant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 29, 2026, 5:59 PM EDT
Active, not recruiting Phase 1 Interventional

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

NCT02608216
View directory record Official record
Conditions
Breast Neoplasm, Metastatic Breast Cancer, Rb+ Breast Cancer
Interventions
[18F]FLT, PET/CT, ribociclib, paclitaxel
Drug · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 29, 2026, 5:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Quad Resection (Hot Snare vs Cold Snare vs Hot EMR vs Cold EMR)

NCT03462706
View directory record Official record
Conditions
Colon Cancer, Colon Polyp, Colon Adenoma
Interventions
Cold Snare, Hot Snare, Cold EMR, Hot EMR
Procedure
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 29, 2026, 5:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of an mHealth Colorectal Cancer Screening Intervention

NCT02088333
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
mCRC intervention, Healthy Lifestyles video
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 74 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
6
States / cities
Advance, North Carolina • Mount Airy, North Carolina • Wilkesboro, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 29, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)

NCT02539433
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
F-18-F-DOPA
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
23 Years to 81 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2015 · Synced Oct 29, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

NCT01963052
View directory record Official record
Conditions
Metastatic Urothelial Cancer
Interventions
AGS15E
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
Birmingham, Alabama • New Haven, Connecticut • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 29, 2026, 5:59 PM EDT
Active, not recruiting Phase 2 Interventional

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

NCT06784947
View directory record Official record
Conditions
Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV
Interventions
Pre-Treatment Biopsy, On-Treatment Biopsy, Tiragolumab, Atezolizumab, Bevacizumab
Procedure · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 29, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms

NCT05438147
View directory record Official record
Conditions
Multiple Sclerosis, Mild Cognitive Impairment, Cancer
Interventions
CT-100 DiNaMo, Care-as-Usual
Other
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
22 Years to 75 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 29, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional Results available

Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

NCT00015847
View directory record Official record
Conditions
Leukemia
Interventions
recombinant interferon alfa, imatinib mesylate
Biological · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
2
States / cities
Chicago, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 29, 2026, 5:59 PM EDT
Recruiting Phase 2 Interventional

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

NCT05534438
View directory record Official record
Conditions
Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Carcinoma, ER+ Breast Cancer, HER2+ Breast Cancer
Interventions
Stereotactic body radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 29, 2026, 5:59 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Mobile Phone Multimedia Messaging Intervention for Breast Cancer Screening

NCT01972048
View directory record Official record
Conditions
Breast Cancer
Interventions
mMammogram, Print brochure
Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 79 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Oct 29, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional Results available

Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)

NCT00506948
View directory record Official record
Conditions
Hematological Malignancies, Myelodysplastic Syndrome, Leukemia, Lymphoma
Interventions
Mycophenolate Mofetil (MMF), Thymoglobulin, Sirolimus, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 29, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Effective Communication for Preventing and Responding to Oncology Adverse Events

NCT01871948
View directory record Official record
Conditions
Cancer
Interventions
"We Want to Know" campaign, Patient survey at 2 time points
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
21 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 29, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00077155
View directory record Official record
Conditions
AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cilengitide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 29, 2026, 5:59 PM EDT
Terminated Early Phase 1 Interventional

Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases

NCT02279992
View directory record Official record
Conditions
Glioma, Brain Neoplasms, Brain Metastasis
Interventions
Vardenafil, Carboplatin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 29, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

NCT05954871
View directory record Official record
Conditions
Colorectal Cancer, Non-Small Cell Lung Cancer
Interventions
GDC-1971, Osimertinib, Cetuximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 29, 2026, 5:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Combined Vaginal Misoprostol and Perivascular Vasopressin

NCT03815344
View directory record Official record
Conditions
Leiomyoma, Laparoscopy, Uterine Myomectomy
Interventions
Standard, Standard-vaginal misoprostol
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 29, 2026, 5:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PALS for Pap Smear Follow up

NCT04070534
View directory record Official record
Conditions
Health Knowledge, Attitudes, Practice
Interventions
PALS
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 29, 2026, 5:59 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

NCT05081609
View directory record Official record
Conditions
Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
Interventions
TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery, Trastuzumab, Trastuzumab emtansine (T-DM1)
Drug · Procedure
Lead sponsor
Ascendis Pharma Oncology Division A/S
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
14
States / cities
Los Angeles, California • Springfield, Illinois • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 29, 2026, 5:59 PM EDT
Active, not recruiting Phase 2 Interventional

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

NCT03817398
View directory record Official record
Conditions
Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
Biospecimen Collection, Drug Withdrawn, Quality-of-Life Assessment, Questionnaire Administration, Tyrosine Kinase Inhibitor
Procedure · Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 25 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
157
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 29, 2026, 5:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Web-based Mindfulness Meditation in Reducing Distress in Participants With Metastatic Gastrointestinal Cancer and Their Caregivers

NCT03528863
View directory record Official record
Conditions
Caregiver, Metastatic Gastrointestinal Carcinoma
Interventions
Online Mindfulness Meditation, Questionnaire Administration
Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 29, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors

NCT00002587
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
paclitaxel, topotecan hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 29, 2026, 5:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Time-Restricted Eating and Mindfulness-Based Stress Reduction to Reduce the Risk of Early-Onset Colorectal Cancer

NCT06022887
View directory record Official record
Conditions
Obesity, Colorectal Cancer, Microbial Colonization, Time Restricted Feeding, Stress, Psychological
Interventions
TRE, MBSR
Behavioral
Lead sponsor
Lisa Tussing-Humphreys
Other
Eligibility
18 Years to 39 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 29, 2026, 5:59 PM EDT